Novartis on track for Q4 EU filing of COPD drug with continued Phase III trial success
This article was originally published in Scrip
Executive Summary
Novartis, Vectura and Sosei have reported that the fifth study (SPARK), in the ten-trial, Phase III, IGNITE programme for the chronic obstructive pulmonary disease (COPD) drug, QVA149, has met its primary endpoint.